No Picture
News

Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress(TM) 2020

Oral Presentation to Highlight New Efficacy Data Measured at Week 16 and Additional Week 12 Efficacy Data Stratified by Baseline Characteristics and Risk Factors

SAN DIEGO, Aug. 20, 2020 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKT… […]

No Picture
News

Low-Cost Nafamostat Blocks SARS-CoV-2 Infection in Human Lung Cells, Preclinical Study Finds

Covistat repurposing generic pancreatitis remedy for oral, inhaled COVID-19 treatments

SAN DIEGO, Aug. 20, 2020 /PRNewswire/ — A preclinical study testing the low-cost generic drug nafamostat in human cells shows it can help block SARS-CoV-2 infecti… […]

No Picture
News

Thermo Fisher Scientific Signs Companion Diagnostic Agreement with Hengrui Therapeutics, Inc.

Companion diagnostic will leverage the Oncomine Precision Assay to identify non-small cell lung cancer patients who may benefit from pyrotinib

CARLSBAD, Calif., Aug. 17, 2020 /PRNewswire/ — Thermo Fisher Scientific has signed a companion diagnostic … […]

No Picture
News

Eclipse Cofounders Publish Foundational Dataset Revealing Extensive Hidden Signals in Human Genes

eCLIP technology solved key problem in matching hundreds of RNA binding proteins to the instruction signals within the RNA code to uncover how RNA binding proteins regulate gene expression

SAN DIEGO, Aug. 11, 2020 /PRNewswire/ — Eclipse Bioinno… […]

No Picture
News

Puradigm, LLC announces successful tests of its proactive air and surface purification technology in deactivating SARS-CoV-2, the virus that causes COVID-19, as well as deactivating coronavirus 229E

Results from a study done by the University of Florida using the SARS-CoV-2 virus show a significant decrease in infectivity of the virus immediately after exposure to Puradigm’s technology and show the virus was undetectable after 24 hours of expos… […]

No Picture
News

Adagio Medical, Inc., reports pre-clinical effectiveness combining their existing ultra-low temperature cryoablation catheter with Pulsed Field Ablation (PFA) in a single Pulsed Field Cryoablation (PFCA) catheter

LAGUNA HILLS, Calif., Aug. 3, 2020 /PRNewswire/ — Adagio Medical, Inc., a leading innovator for the treatment of atrial fibrillation (AFib) and ventricular tachycardia (VT), and developer of the intelligent Continuous Lesion Ablation System (iCLAS™… […]

No Picture
News

Viking Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH; New Data from 12-Week Phase 2 Trial to be Highlighted at EASL- IND Filed for VK0214 in X-ALD; Phase 1 Trial Expected to Begin Q3 2020- Ba… […]

No Picture
News

Exonbio launches high affinity SARS-CoV-2 rabbit monoclonal antibodies to accelerate the global IVD and research community efforts

SAN DIEGO, July 23, 2020 /PRNewswire/ — Exonbio, a leading recombinant antibody CRO company now launches the SARS-CoV-2 Nucleocapsid recombinant monoclonal antibodies for the global IVD and research communities in support of efforts to combat the p… […]

No Picture
News

Regulus Therapeutics Completes Dosing in Phase 1 Multiple Ascending Dose Study of RGLS4326 in Healthy Volunteers for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

LA JOLLA, Calif., July 22, 2020 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced … […]

No Picture
News

Singlera Genomics and Fudan University unveiled results demonstrating detection of five common cancers earlier than standard test

SAN DIEGO and SHANGHAI, July 21, 2020 /PRNewswire/ — Fudan University’s Taizhou Health Science Institute and Singlera Genomics, focused on non-invasive early cancer detection, today announce the publication of a peer reviewed manuscript demonstrati… […]

No Picture
News

Singlera Genomics and Fudan University unveiled results demonstrating detection of five common cancers earlier than standard test

SAN DIEGO and SHANGHAI, July 21, 2020 /PRNewswire/ — Fudan University’s Taizhou Health Science Institute and Singlera Genomics, focused on non-invasive early cancer detection, today announce the publication of a peer reviewed manuscript demonstrati… […]

No Picture
News

Amplyx Announces Positive Top-line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix

Fosmanogepix met primary efficacy endpoint and demonstrated favorable safety profile in first-line treatment of invasive Candida infections

SAN DIEGO, July 20, 2020 /PRNewswire/ — Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical company de… […]

No Picture
News

Heron Therapeutics Announces Initiation of Phase 2 Clinical Study of CINVANTI® for the Treatment of COVID-19

SAN DIEGO, July 16, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet … […]

No Picture
News

Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain

– Complete Response Letter Requests Additional Non-Clinical Information — No Clinical Safety or Efficacy Issues and No Chemistry, Manufacturing and Controls (CMC) Issues Identified — Conference Call and Webcast Today at 9:00 a.m. ET –

SAN DIEGO, Ju… […]

No Picture
News

Cardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AML

– Phase 1b: 7 (33%) of evaluable patients achieved an objective response, with a complete response (CR/CRi) in 5 (31%) patients treated at the four highest onvansertib dose levels- 3 (60%) of the 5 patients remain on treatment with durable response d… […]

No Picture
News

Dermata Announces Positive Results from its Phase 2b Clinical Trial of Once Weekly Topical Application of DMT310 for the Treatment of Moderate to Severe Acne Vulgaris

– DMT310 achieved IGA success (2-point change & 0 or 1) in 44.4% of patients versus 17.8% of placebo patients (p=0.0003)- DMT310 saw a -15.6 mean change from baseline in inflammatory lesion count versus a -10.8 mean change from baseline for placebo (p=… […]

No Picture
News

Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation

— Initiation of Expanded Access Program follows FDA granting Fast Track Designation of onvansertib for second-line treatment of patients with KRAS-mutation mCRC– Expanded Access Program provides pathway for patients to gain access to treatment with o… […]

No Picture
News

Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020

– Crinecerfont Demonstrates Meaningful Reductions in Key Disease Biomarkers After 14 Days of Treatment- Initiation of Global Registrational Study of Crinecerfont in Adults Planned for Second Half 2020

SAN DIEGO, June 8, 2020 /PRNewswire/ — Neur… […]

No Picture
News

Heron Therapeutics Announces Publication of Results from Study 209, a Phase 2b Study of HTX-011 in Patients Undergoing Total Knee Arthroplasty

SAN DIEGO, June 4, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet … […]

No Picture
News

Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals’ VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme

GBM AGILE is the world’s first global adaptive clinical trial platform for glioblastoma with regulatory support as a registrational studyVAL-083 selected as the next investigational therapy to be evaluated across multiple international trial sitesReduc… […]

No Picture
News

Qualigen Therapeutics Releases FastPack® SARS-CoV-2 Antibody Diagnostic Test to University of Louisville to Conduct Validation Studies

CARLSBAD, Calif., June 2, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) announced today that the Company has released a pre-launch supply of its proposed FastPack® SARS-CoV-2 IgG Immunoassay diagnostic tes… […]

No Picture
News

DelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of VAL-083 at the 2020 American Association for Cancer Research Virtual Annual Meeting II

SAN DIEGO, June 1, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that two posters updating r… […]

No Picture
News

Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO

– Positive data presented at ASCO follows announcement of Fast Track Designation granted by the FDA for onvansertib in second-line treatment of patients with KRAS-mutated mCRC- 89% overall clinical benefit achieved – objective response rate (ORR) of … […]

No Picture
News

Ajinomoto Bio-Pharma Services Signs Manufacturing Agreement with Humanigen for Lenzilumab, Currently in FDA-Approved Phase III Study for COVID-19

SAN DIEGO, May 27, 2020 /PRNewswire/ — Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce it has entered into a manufacturing agreement w… […]

No Picture
News

Maintaining a Healthy Upper Respiratory Tract Microbiome May Help Prevent Secondary Infections in Influenza A Patients

An influenza-impacted upper respiratory tract microbiome may invite opportunistic bacterial pathogens

LA JOLLA, Calif., May 26, 2020 /PRNewswire/ — Scientists from the J. Craig Venter Institute (JCVI), Icahn School of Medicine at Mount Sinai, and Po… […]

No Picture
News

Neurelis Announces Total Of Nine Poster Presentations For The AANN, AMCP, And AAN Annual Meetings

– Data supports pharmacokinetic and safety profile for Neurelis’ lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in pediatric patients 6 years of age and older, adolescents, and adults-… […]

No Picture
News

Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases

Multi-Target Collaboration Leverages Vividion’s Screening Platform to Discover and Develop Highly Selective Small Molecules for E3 Ligases and Select Oncology and Immunology TargetsVividion Receives $135 Million Upfront Payment With Potential for Multi… […]